Hypertension–A significant disease

Hypertension affects over 1 billion people worldwide and an estimated 80 million in the United States alone.

Hypertension directly increases the risk for cardiovascular disease. According to the American Heart Association, elevated blood pressure at or above 140/90 mmHg was found in:

  • 77% of American who have had a first stroke
  • 69% of Americans who have had a first heart attack
  • 74% of Americans who have congestion heart failure

While over 75% of Americans with high blood pressure are using antihypertensive medication, nearly half of patients with hypertension do not have it under control1,2.


TARGET BP I Clinical Trial

Under an Investigational New Drug (IND) application, Ablative Solutions is studying the Peregrine System™ Kit for catheter-based renal denervation for the treatment of uncontrolled hypertension with targeted delivery of alcohol, an investigational drug. Under the IND, Ablative Solutions will conduct a multi-center, double-blind, randomized, sham-controlled trial to evaluate its drug-device combination therapy for the treatment of uncontrolled hypertension despite pharmacologic treatment, in conjunction with antihypertensive medical therapy.

The trial, called TARGET BP I, is projected to begin in the United States and is expected to enroll approximately 100 patients in approximately 20 centers globally. The Peregrine System Kit includes a co-packaged Peregrine Catheter and Dehydrated alcohol. This combination product is an investigational product intended as a treatment for persistent hypertension despite optimal medical therapy, in conjunction with anti-hypertensive medications.

For more information, please visit  TARGET BP I

1American Heart Association, 2016 Heart Disease and Stroke Statistics Update
2CDC, NCHS Data Brief No. 220, November 2015